Moderna (NASDAQ: MRNA), announced on Monday that it has mutually agreed with Gavi, the Vaccine Alliance, to cancel the remaining pending orders under the current COVID-19 vaccine supply agreement for the rest of the year. The biotechnology company developing messenger RNA (mRNA) therapeutics and vaccines, and Gavi have decided instead to create a new framework that would enable Gavi to purchase up to 100 million doses in 2023 on behalf of the COVAX Facility. This new framework will ensure access to updated variant-specific COVID-19 vaccines for low- and middle-income countries.
https://www.tipranks.com/news/moderna-updates-current-deal-with-gavi-securing-access-to-covid-19-vaccines-in-low-income-countries?utm_source=advfn.com&utm_medium=referral
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Moderna Charts.